When was ALX Oncology founded?

ALX Oncology was founded in 2015 and raised its 1st funding round within a year of its incorporation.

Where is ALX Oncology located?

ALX Oncology is headquartered in Burlingame, United States. It is registered at South San Francisco,California.

How many employees does ALX Oncology have?

As of Mar 31, 2026, the latest employee count at ALX Oncology is 59.

Is ALX Oncology a funded company?

ALX Oncology is a funded company, having raised a total of $123M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 21, 2015.

When was the latest funding round of ALX Oncology?

ALX Oncology's latest funding was a $***** Series C round on Feb 12, 2020, with participation from 9 investors.

What is the annual revenue of ALX Oncology?

Annual revenue of ALX Oncology is between $1M and $10M as on Dec 31, 2020

Where does ALX Oncology rank among its competitors?

ALX Oncology ranks 225th amongst 3245 active competitors, of which 1125 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of ALX Oncology?

ALX Oncology's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Senti Bio secured the most recent funding round in May, 2026.

ALX Oncology - 2026 Company Profile, Team, Funding, Competitors & Financials

ALX Oncology is a public company based in Burlingame (United States), founded in 2015 by Corey Goodman. It operates as a Developer of immuno-oncology therapies for cancer treatment. ALX Oncology has raised $123M in funding from Vivo Capital. The company has 3245 active competitors, including 1125 funded and 771 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of immuno-oncology therapies for cancer treatment. The lead product candidate ALX148 is a checkpoint inhibitor that comprises an affinity CD47 binding domain of SIRPα linked to an inactive Fc region of a human immunoglobulin. It binds CD47 and inhibits the CD47-SIRPα signaling pathway.

Website: alxoncology.com
Social
Email ID: *****@alxoncology.com
Registered Address: South San Francisco,California

Key Metrics

Founded Year

2015

Location

Burlingame, United States

Stage

Public

Total Funding

$123M in 2 rounds

Latest Funding Round

Series C, Feb 12, 2020, $*****

Investors

Vivo Capital & 11 more

Ranked

225^th among 3245 active competitors

Annual Revenue

$1M - $10M as on Dec 31, 2020

Employee Count

59 as on Mar 31, 2026

Investment & Acquisitions

ScalmiBio

Similar Companies

BeiGene & 597 more

Exit Details

Public

View ALX Oncology's full profile

ALX Oncology is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ALX ONCOLOGY HOLDINGS INC CIN: 1810182 , United States, Active	Mar 31, 2020	$1M - $10M (As on Dec 31, 2020)	-	-
ALX ONCOLOGY LIMITED CIN: 558988 , Belgium, Active	Mar 12, 2015	-	41 (As on Dec 31, 2021)	-
Alx Oncology Inc. CIN: 472849014 , United States, Active	Dec 31, 1999	-	59 (As on Dec 31, 2022)	-

ALX Oncology got listed on Jul 17, 2020.

Click here to take a look at ALX Oncology's IPO in detail

ALX Oncology has raised a total funding of $123M over 2 rounds. Its first funding round was on May 21, 2015. Its latest funding round was a Series C round on Feb 12, 2020 for $*****. 9 investors participated in its latest round. ALX Oncology has 12 institutional investors.

Here is the list of recent funding rounds of ALX Oncology:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 12, 2020	1865829	Series C	9542186	2629010	1579279	8332867
May 21, 2015	6372722	Series A	4818070	1347452	4645282	6287189

Access funding benchmarks and valuations. Sign up today!

View details of ALX Oncology's funding rounds and investors

The founders of ALX Oncology is Corey Goodman.

Here are the details of ALX Oncology's key team members:

Corey Goodman: Co-Founder of ALX Oncology and founder of 1 other company. They are also an angel investor in 1 startup.
Contact Info: 1 email address

View details of ALX Oncology's Founder profiles and Board Members

ALX Oncology's employee count trend

ALX Oncology has 59 employees as of Mar 26. Here is ALX Oncology's employee count trend over the years:

Uncover ALX Oncology's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ALX Oncology include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of ALX Oncology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
8th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
10th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
225th	ALX Oncology 2015, Burlingame (United States), Public	Developer of immuno-oncology therapies for cancer treatment	$123M	BVF Partners, Foresite Capital & 10 others	59/100